This article is part of the supplement: Basic science, rationale, background and future of abatacept

Highly Accessed Email this article to a friend

The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis

Eric M Ruderman* and Richard M Pope

Arthritis Research & Therapy 2005, 7(Suppl 2):S21-S25 doi:10.1186/ar1688

Fields marked * are required


Multiple email addresses should be separated with commas or semicolons.
How can I ensure that I receive Arthritis Research & Therapy's emails?